By Brandon Miller and Natalie Pollock, Clarkston Consulting GLP-1s are on track to become the biggest drug class in history, with annual sales projected to surpass $100 billion over the next five years.1 As of 2025, roughly 10 million Americans2 are on GLP-1s, for both treatment of type 2 diabetes and weight loss, and that number is expected to reach 25 million by 2030. This is especially significant because the pharmaceutical industry is currently shifting gears.